FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

BACKGROUND: ALM201 is a therapeutic peptide derived from FKBPL that has previously undergone preclinical and clinical development for oncology indications and has completed a Phase 1a clinical trial in ovarian cancer patients and other advanced solid tumours. METHODS: In vitro, cancer stem cell (CSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Annett, Stephanie, Moore, Gillian, Short, Amy, Marshall, Andrea, McCrudden, Cian, Yakkundi, Anita, Das, Sudipto, McCluggage, W. Glenn, Nelson, Laura, Harley, Ian, Moustafa, Nermeen, Kennedy, Catherine J., deFazio, Anna, Brand, Alison, Sharma, Raghwa, Brennan, Donal, O’Toole, Sharon, O’Leary, John, Bates, Mark, O’Riain, Ciarán, O’Connor, Darran, Furlong, Fiona, McCarthy, Helen, Kissenpfennig, Adrien, McClements, Lana, Robson, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000737/
https://www.ncbi.nlm.nih.gov/pubmed/31772325
http://dx.doi.org/10.1038/s41416-019-0649-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000737/
https://www.ncbi.nlm.nih.gov/pubmed/31772325
http://dx.doi.org/10.1038/s41416-019-0649-5

Ejemplares similares